{"title":"脂蛋白(a)作为2型糖尿病患者糖尿病视网膜病变的预测因子:一项系统综述。","authors":"Mohammad Sadra Gholami Chahkand, Fatemeh Esmaeilpour Moallem, Abolfazl Qezelgachi, Kiana Seifouri, Armin Pesaran Afsharian, Farzad Sheikhzadeh, Atefe Poursalehi, Fateme Sadat Fani Sadrabadi, Mehrnush Saghab Torbati, Mohaddese Ramezanzade, Goharsharieh Alishiri, Arina Ansari, Emad Zare Dehabadi, Saeed Karimi Matloub, Zahra Sheikh, Niloofar Deravi, Saba Mehrtabar, Fatemeh Chichagi, Neda Faal Hamedanchi, Mohammadreza Arzaghi, Mahla Asadi, Parisa Alsadat Dadkhah, Akram Ansari","doi":"10.1177/14791641231197114","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes-the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy.</p><p><strong>Methods: </strong>A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention.</p><p><strong>Result: </strong>17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy.</p><p><strong>Conclusion: </strong>High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685788/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review.\",\"authors\":\"Mohammad Sadra Gholami Chahkand, Fatemeh Esmaeilpour Moallem, Abolfazl Qezelgachi, Kiana Seifouri, Armin Pesaran Afsharian, Farzad Sheikhzadeh, Atefe Poursalehi, Fateme Sadat Fani Sadrabadi, Mehrnush Saghab Torbati, Mohaddese Ramezanzade, Goharsharieh Alishiri, Arina Ansari, Emad Zare Dehabadi, Saeed Karimi Matloub, Zahra Sheikh, Niloofar Deravi, Saba Mehrtabar, Fatemeh Chichagi, Neda Faal Hamedanchi, Mohammadreza Arzaghi, Mahla Asadi, Parisa Alsadat Dadkhah, Akram Ansari\",\"doi\":\"10.1177/14791641231197114\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes-the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy.</p><p><strong>Methods: </strong>A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention.</p><p><strong>Result: </strong>17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy.</p><p><strong>Conclusion: </strong>High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.</p>\",\"PeriodicalId\":93978,\"journal\":{\"name\":\"Diabetes & vascular disease research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685788/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & vascular disease research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/14791641231197114\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & vascular disease research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/14791641231197114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review.
Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes-the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy.
Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention.
Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy.
Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
